Clinical Trial Update: Bevacizumab for the Treatment of Corneal Neovascularization [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating bevacizumab for corneal neovascularization, with the trial status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Neovascularization

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Corneal Neovascularization | Phase 2 | Status: UNKNOWN